| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Simon Cervenka, Sven E Pålhagen, Robert A Comley, Georgios Panagiotidis, Zsolt Cselényi, Julian C Matthews, Robert Y Lai, Christer Halldin, Lars Fard. Support for dopaminergic hypoactivity in restless legs syndrome: a PET study on D2-receptor binding. Brain : a journal of neurology. vol 129. issue Pt 8. 2006-09-29. PMID:16816393. |
both interpretations are consistent with the hypothesis of hypoactive dopaminergic neurotransmission in rls, as increased receptor levels can be owing to receptor upregulation in response to low levels of endogenous dopamine. |
2006-09-29 |
2023-08-12 |
human |
| Satoshi Ohashi, Atsushi Mori, Naoki Kurihara, Yasuhide Mitsumoto, Masami Naka. Age-related severity of dopaminergic neurodegeneration to MPTP neurotoxicity causes motor dysfunction in C57BL/6 mice. Neuroscience letters. vol 401. issue 1-2. 2006-09-28. PMID:16581184. |
an extensive dopaminergic cell loss was found in both the striatum and substantia nigra of older mice given one and two injections of mptp with marked decrease in striatal dopamine (da) levels, but not young mice. |
2006-09-28 |
2023-08-12 |
mouse |
| Spiridon Papapetropoulo. Regional alpha-synuclein aggregation, dopaminergic dysregulation, and the development of drug-related visual hallucinations in Parkinson's disease. The Journal of neuropsychiatry and clinical neurosciences. vol 18. issue 2. 2006-09-28. PMID:16720791. |
denervation supersensitivity of dopaminergic receptors in ventral striatal and mesocorticolimbic areas as well as defective synaptic buffering ability due to the loss of dopaminergic presynaptic terminals and dopamine transporter may be among the key factors leading to visual hallucinations in parkinson's disease. |
2006-09-28 |
2023-08-12 |
Not clear |
| Cristina M Bäckman, Nasir Malik, Yajun Zhang, Lufei Shan, Alex Grinberg, Barry J Hoffer, Heiner Westphal, Andreas C Toma. Characterization of a mouse strain expressing Cre recombinase from the 3' untranslated region of the dopamine transporter locus. Genesis (New York, N.Y. : 2000). vol 44. issue 8. 2006-09-28. PMID:16865686. |
the dopamine transporter (dat) is highly expressed in dopaminergic neurons of the ventral mesencephalon and regulates neurotransmission by transporting da back into the presynaptic terminals. |
2006-09-28 |
2023-08-12 |
mouse |
| Fengming Yue, Li Cui, Kohei Johkura, Naoko Ogiwara, Katsunori Sasak. Induction of midbrain dopaminergic neurons from primate embryonic stem cells by coculture with sertoli cells. Stem cells (Dayton, Ohio). vol 24. issue 7. 2006-09-27. PMID:16822882. |
these sertoli cell-induced dopaminergic cells can release dopamine when depolarized by high k(+). |
2006-09-27 |
2023-08-12 |
mouse |
| Michael A Nader, Drake Morgan, H Donald Gage, Susan H Nader, Tonya L Calhoun, Nancy Buchheimer, Richard Ehrenkaufer, Robert H Mac. PET imaging of dopamine D2 receptors during chronic cocaine self-administration in monkeys. Nature neuroscience. vol 9. issue 8. 2006-09-27. PMID:16829955. |
positron emission tomography was used in 12 rhesus macaques to determine if dopamine d2 receptor availability was associated with the rate of cocaine reinforcement, and to study changes in brain dopaminergic function during maintenance of and abstinence from cocaine. |
2006-09-27 |
2023-08-12 |
monkey |
| Jacob U Fog, Habibeh Khoshbouei, Marion Holy, William A Owens, Christian Bjerggaard Vaegter, Namita Sen, Yelyzaveta Nikandrova, Erica Bowton, Douglas G McMahon, Roger J Colbran, Lynette C Daws, Harald H Sitte, Jonathan A Javitch, Aurelio Galli, Ulrik Gethe. Calmodulin kinase II interacts with the dopamine transporter C terminus to regulate amphetamine-induced reverse transport. Neuron. vol 51. issue 4. 2006-09-26. PMID:16908408. |
camkiialpha stimulated dopamine efflux via dat in response to amphetamine in heterologous cells and in dopaminergic neurons. |
2006-09-26 |
2023-08-12 |
Not clear |
| Mattia Gambarin, Angelo Antonini, Giuseppe Moretto, Paolo Bovi, Silvia Romito, Antonio Fiaschi, Michele Tinazz. Pisa syndrome without neuroleptic exposure in a patient with Parkinson's disease: case report. Movement disorders : official journal of the Movement Disorder Society. vol 21. issue 2. 2006-09-25. PMID:16161148. |
because dopamine transporter imaging revealed bilateral and symmetrical reduction of striatal uptake, we suggest that ps is not primarily related to side differences in dopaminergic denervation or drug exposure. |
2006-09-25 |
2023-08-12 |
Not clear |
| Juliane Hamann, Hans Rommelspacher, Alexander Storch, Heinz Reichmann, Gabriele Gill. Neurotoxic mechanisms of 2,9-dimethyl-beta-carbolinium ion in primary dopaminergic culture. Journal of neurochemistry. vol 98. issue 4. 2006-09-21. PMID:16787411. |
the beta-carboline caused preferential death of dopaminergic neurones, which could not be attributed to cellular uptake via the dopamine transporter. |
2006-09-21 |
2023-08-12 |
mouse |
| Neil Vasdev, Sridhar Natesan, Laurent Galineau, Armando Garcia, Winston T Stableford, Patrick McCormick, Philip Seeman, Sylvain Houle, Alan A Wilso. Radiosynthesis, ex vivo and in vivo evaluation of [11C]preclamol as a partial dopamine D2 agonist radioligand for positron emission tomography. Synapse (New York, N.Y.). vol 60. issue 4. 2006-09-20. PMID:16786538. |
it was the goal of this work to radiolabel (s)-(-)propyl-3-(3-hydroxyphenyl)piperidine (preclamol; (-)3-ppp), a partial dopamine d2 agonist with carbon-11 (half-life=20.4 min) and to evaluate this novel radiopharmaceutical for dopaminergic imaging in rodent models. |
2006-09-20 |
2023-08-12 |
rat |
| Yasushi Ishida, Keiichi Kawai, Yasuhiro Magata, Ryuichiro Takeda, Hiroyuki Hashiguchi, Hiroshi Abe, Takahiro Mukai, Hideo Saj. Changes in dopamine D2 receptors and 6-[18F]fluoro-L-3,4-dihydroxyphenylalanine uptake in the brain of 6-hydroxydopamine-lesioned rats. Neuro-degenerative diseases. vol 1. issue 2-3. 2006-09-20. PMID:16908982. |
we studied tracer distributions in positron emission tomography of ligands for dopamine d1 receptors ([11c]sch23390) and d2 receptors ([11c]raclopride) and the dopamine precursor analog 6-[18f]fluoro-l-3,4-dihydroxyphenylalanine ([18f]fdopa), as a measurement of presynaptic dopaminergic function, in the brain after 6-hydroxydopamine lesioning of the medial forebrain bundle in rats. |
2006-09-20 |
2023-08-12 |
rat |
| K P Datla, V Zbarsky, D T Dexte. Effects of anaesthetics on the loss of nigrostriatal dopaminergic neurons by 6-hydroxydopamine in rats. Journal of neural transmission (Vienna, Austria : 1996). vol 113. issue 5. 2006-09-19. PMID:16082506. |
as these anaesthetics are known to modulate uptake and turnover of dopamine and that 6-ohda-induced neurotoxicity is also dependents on uptake/turnover, we studied the effects of these anaesthetics on the extent of nigrostriatal dopaminergic damage caused by 6-ohda. |
2006-09-19 |
2023-08-12 |
rat |
| K P Datla, V Zbarsky, D T Dexte. Effects of anaesthetics on the loss of nigrostriatal dopaminergic neurons by 6-hydroxydopamine in rats. Journal of neural transmission (Vienna, Austria : 1996). vol 113. issue 5. 2006-09-19. PMID:16082506. |
infusion of 8 microg of 6-ohda into the medial forebrain bundle significantly reduced the numbers of dopaminergic cells in nigra and striatal concentrations of dopamine in animals anaesthetized with fentanyl/medetomidine, etorphine/methotrimeprazine and isoflurane but not with ketamine/xylazine. |
2006-09-19 |
2023-08-12 |
rat |
| Oliver Pogarell, Walter Koch, Franz J Gildehaus, Andreas Kupsch, Olle Lindvall, Wolfgang H Oertel, Klaus Tatsc. Long-term assessment of striatal dopamine transporters in Parkinsonian patients with intrastriatal embryonic mesencephalic grafts. European journal of nuclear medicine and molecular imaging. vol 33. issue 4. 2006-09-19. PMID:16447045. |
single-photon emission computed tomography (spect) of striatal dopamine transporters (dat) has been used to demonstrate presynaptic dopaminergic dysfunction and to monitor the progression of parkinson's disease. |
2006-09-19 |
2023-08-12 |
human |
| Roshan Cools, Lee Altamirano, Mark D'Esposit. Reversal learning in Parkinson's disease depends on medication status and outcome valence. Neuropsychologia. vol 44. issue 10. 2006-09-19. PMID:16730032. |
we investigated the role of dopamine in distinct forms of reversal shifting by comparing two groups of patients with mild parkinson's disease (pd), one on and one off their normal dopaminergic medication. |
2006-09-19 |
2023-08-12 |
Not clear |
| Masanaga Ikegami, Yukio Ichitani, Tatsuhisa Takahashi, Tsuneo Iwasak. Compensatory increase in extracellular dopamine in the nucleus accumbens of adult rats with neonatal 6-hydroxydopamine treatment. Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology. vol 26. issue 3. 2006-09-19. PMID:16866211. |
to characterize a compensatory function of the dopaminergic system of residual dopamine (da) neurons in the mesolimbic pathway with da-depleting lesions, we compared tissue and extracellular concentrations of da and its metabolites in the nucleus accumbens (nacc) of adult rats with neonatal 6-hydroxydopamine (6-ohda) treatment with those of control rats with neonatal vehicle treatment using high-performance liquid chromatography. |
2006-09-19 |
2023-08-12 |
rat |
| Shigeyuki Chaki, Ryoko Yoshikawa, Shigeru Okuyam. Group II metabotropic glutamate receptor-mediated regulation of dopamine release from slices of rat nucleus accumbens. Neuroscience letters. vol 404. issue 1-2. 2006-09-18. PMID:16781059. |
these results show that group ii mglurs may play a more significant role in regulating dopamine release than group iii mglurs, and that the group ii mglurs may negatively regulate dopamine release, presumably through those expressed at the dopaminergic nerve terminals or through those expressed at glutamatergic nerve terminals in the nucleus accumbens. |
2006-09-18 |
2023-08-12 |
rat |
| Luciana Mosca, Eugenio Lendaro, Maria d'Erme, Sonia Marcellini, Sonia Moretti, Maria Anna Rose. 5-S-Cysteinyl-dopamine effect on the human dopaminergic neuroblastoma cell line SH-SY5Y. Neurochemistry international. vol 49. issue 3. 2006-09-15. PMID:16549224. |
in recent years a catechol-thioether metabolite of dopamine, 5-s-cysteinyl-dopamine, has been identified in certain dopaminergic regions of the brain, notably the substantia nigra. |
2006-09-15 |
2023-08-12 |
human |
| Mari Oksman, Heikki Tanila, Leonid Yavic. Brain reward in the absence of alpha-synuclein. Neuroreport. vol 17. issue 11. 2006-09-15. PMID:16837852. |
recent studies revealed its role as a negative regulator of dopamine release in the nigrostriatal dopaminergic system. |
2006-09-15 |
2023-08-12 |
mouse |
| C Warren Olanow, José A Obeso, Fabrizio Stocch. Drug insight: Continuous dopaminergic stimulation in the treatment of Parkinson's disease. Nature clinical practice. Neurology. vol 2. issue 7. 2006-09-15. PMID:16932589. |
continuous dopaminergic stimulation is a therapeutic strategy for the management of parkinson's disease, which proposes that dopaminergic agents that provide continuous stimulation of striatal dopamine receptors will delay or prevent the onset of levodopa-related motor complications. |
2006-09-15 |
2023-08-12 |
Not clear |